Replies to post #174437 on Anavex Life Sciences Corp (AVXL)

[OFP]

The simplest explanation for why Australian sites are up and running and the North American ones aren't... The sites aren't ready and the Anavex 2-73 precision medicine trial requires more efficiency than the U.S. system can currently provide.

There is absolutely no basis for that assertion. The simplest explanation is that AVXL is in the FDA woodshed and has been there >1 year. This is an AVXL FAILURE not a problem with the US system. Hundreds of trials are started every year in the US and any barriers to initiation (inefficiencies in your parlance) are worked out in weeks not years.

[nidan7500]

ACTC investment is long overdue. The program outline shows clearly they will spend money to set up a set of basic controls and infrastructure which one would expect was basic and already in place. Good news is, they are starting to address the public need, the bad news is they are way late and the investment is (according to simple math) is a little light at roughly $2.64 per current/projected 5 yr AD patients per year. So, good news is they finally are starting to put resources in place to address AD national needs. Bad news is the program is underfunded and below the radar.